Personensuche
Personensuche
Es wurde 1 Person gefunden.
Aktuelle Veranstaltungen
Vergangene Veranstaltungen (max. 10)
-
2022 WS
-
2022 SS
-
2021 WS
-
2021 SS
Die folgenden Publikationen sind in der Online-Universitätsbibliographie der Universität Duisburg-Essen verzeichnet. Weitere Informationen finden Sie gegebenenfalls auch auf den persönlichen Webseiten der Person.
-
A Phase II Study of Nab-Paclitaxel and Gemcitabine as First-Line Therapy in Patients with Cholangiocarcinoma Ineligible for Cisplatin-Based Chemotherapy (NACHO)In: Oncology Research and Treatment Jg. 46 (2023) Nr. 3, S. 89 - 99ISSN: 2296-5262; 2296-5270; 1423-0240; 0378-584XOnline Volltext: dx.doi.org/
-
Clinical Outcome and Treatment Sequences of Patients with Advanced Pancreatic Cancer Treated with Contemporary Chemotherapy ProtocolsIn: Oncology Research and Treatment Jg. 46 (2023) Nr. 4, S. 140 - 150ISSN: 2296-5262; 2296-5270; 1423-0240; 0378-584XOnline Volltext: dx.doi.org/
-
Combination of the STING Agonist MIW815 (ADU-S100) and PD-1 Inhibitor Spartalizumab in Advanced/Metastatic Solid Tumors or Lymphomas : An Open-Label, Multicenter, Phase Ib StudyIn: Clinical Cancer Research Jg. 29 (2023) Nr. 1, S. 110 - 121ISSN: 1557-3265; 1078-0432Online Volltext: dx.doi.org/
-
Deep learning-based assessment of body composition and liver tumour burden for survival modelling in advanced colorectal cancerIn: Journal of Cachexia, Sarcopenia and Muscle Jg. 14 (2023) Nr. 1, S. 545 - 552ISSN: 2190-6009; 2190-5991Online Volltext: dx.doi.org/ (Open Access)
-
Depth of response of induction therapy and consecutive maintenance treatment in patients with RAS wild-type metastatic colorectal cancer : An analysis of the PanaMa trial (AIO KRK 0212)In: European Journal of Cancer (EJC) Jg. 178 (2023) S. 37 - 48ISSN: 1879-0852; 0959-8049; 1879-2995Online Volltext: dx.doi.org/
-
Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck : KESTREL, a randomized, open-label, phase III studyIn: Annals of Oncology Jg. 34 (2023) Nr. 3, S. 262 - 274ISSN: 1569-8041; 0923-7534Online Volltext: dx.doi.org/ (Open Access)
-
Favorable survival outcomes in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer sequentially treated with a tyrosine kinase inhibitor and osimertinib in a real-world settingIn: Journal of Cancer Research and Clinical Oncology (2023) in pressISSN: 1432-1335; 0171-5216; 0084-5353; 0301-1585Online Volltext: dx.doi.org/ (Open Access)
-
Fibroblast-Activation Protein PET and Histopathology in a Single-Center Database of 324 Patients and 21 Tumor EntitiesIn: Journal of Nuclear Medicine (JNM) / Society of Nuclear Medicine and Molecular Imaging (SNMMI) (Hrsg.) Jg. 64 (2023) Nr. 5, S. 711 - 716ISSN: 1535-5667; 0161-5505; 2159-662X; 0022-3123; 0097-9058Online Volltext: dx.doi.org/
-
Overall survival with cetuximab every-2-weeks versus standard once-weekly administration schedule for first-line treatment of RAS wild-type metastatic colorectal cancer in patients with left- and right-sided primary tumour locationIn: European Journal of Cancer (EJC) Jg. 180 (2023) S. 85 - 88ISSN: 1879-0852; 0959-8049; 1879-2995Online Volltext: dx.doi.org/
-
PSMA-Directed Imaging and Therapy of Salivary Gland Tumors : A Single-Center Retrospective StudyIn: Journal of Nuclear Medicine (JNM) / Society of Nuclear Medicine and Molecular Imaging (SNMMI) (Hrsg.) Jg. 64 (2023) Nr. 3, S. 372 - 378ISSN: 1535-5667; 0161-5505; 2159-662X; 0022-3123; 0097-9058Online Volltext: dx.doi.org/
-
Real-Life Experience in the Treatment of Intrahepatic Cholangiocarcinoma by ⁹⁰Y Radioembolization : A Multicenter Retrospective StudyIn: Journal of Nuclear Medicine (JNM) / Society of Nuclear Medicine and Molecular Imaging (SNMMI) (Hrsg.) Jg. 64 (2023) Nr. 4, S. 529 - 535ISSN: 1535-5667; 0161-5505; 2159-662X; 0022-3123; 0097-9058Online Volltext: dx.doi.org/
-
A prognostic systemic inflammation score (SIS) in patients with advanced intrahepatic cholangiocarcinomaIn: Journal of Cancer Research and Clinical Oncology (2022) in pressISSN: 1432-1335; 0171-5216; 0084-5353; 0301-1585Online Volltext: dx.doi.org/ (Open Access)
-
FOLFOX plus panitumumab or FOLFOX alone as additive therapy following R0/1 resection of RAS wild-type colorectal cancer liver metastases : The PARLIM trial (AIO KRK 0314)In: European Journal of Cancer (EJC) Jg. 173 (2022) S. 297 - 306ISSN: 1879-0852; 0959-8049; 1879-2995Online Volltext: dx.doi.org/
-
Heilung ohne Operation und Radiochemotherapie beim lokal fortgeschrittenen, Mismatch-Reparatur-defizienten Rektumkarzinom?In: Coloproctology Jg. 44 (2022) Nr. 5, S. 357 - 360ISSN: 0174-2442; 1615-6730Online Volltext: dx.doi.org/
-
Identification of a new prognostic score for patients with high-grade metastatic GEP-NEN treated with palliative chemotherapyIn: Journal of Cancer Research and Clinical Oncology (2022) in pressISSN: 1432-1335; 0171-5216; 0084-5353; 0301-1585Online Volltext: dx.doi.org/ (Open Access)
-
Long-term Outcomes with Nivolumab as First-line Treatment in Recurrent or Metastatic Head and Neck Cancer : Subgroup Analysis of CheckMate 141In: The Oncologist Jg. 27 (2022) Nr. 2, S. e194 - e198ISSN: 1083-7159; 2159-8401; 1549-490XOnline Volltext: dx.doi.org/ (Open Access)
-
PET-directed combined modality therapy for gastroesophageal junction cancer : Results of the multicentre prospective MEMORI trial of the German Cancer Consortium (DKTK)In: European Journal of Cancer (EJC) Jg. 175 (2022) S. 99 - 106ISSN: 1879-0852; 0959-8049; 1879-2995Online Volltext: dx.doi.org/
-
Panitumumab Plus Fluorouracil and Folinic Acid Versus Fluorouracil and Folinic Acid Alone as Maintenance Therapy in RAS Wild-Type Metastatic Colorectal Cancer : The Randomized PANAMA Trial (AIO KRK 0212)In: Journal of Clinical Oncology (JCO) Jg. 40 (2022) Nr. 1, S. 72 - 82ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/ (Open Access)
-
Photochemical Internalization of Gemcitabine Is Safe and Effective in Locally Advanced Inoperable CholangiocarcinomaIn: The Oncologist Jg. 27 (2022) Nr. 6, S. 430 - 431, e423 - e433ISSN: 1083-7159; 2159-8401; 1549-490XOnline Volltext: dx.doi.org/ (Open Access)
-
Serial Analysis of Gene Mutations and Gene Expression during First-Line Chemotherapy against Metastatic Colorectal Cancer : Identification of Potentially Actionable Targets within the Multicenter Prospective Biomarker Study REVEALIn: Cancers Jg. 14 (2022) Nr. 15,ISSN: 2072-6694Online Volltext: dx.doi.org/ (Open Access)
-
Survival after secondary liver resection in metastatic colorectal cancer : Comparing data of three prospective randomized European trials ( LICC , CELIM , FIRE ‐3)In: International Journal of Cancer Jg. 150 (2022) Nr. 8, S. 1341 - 1349ISSN: 0020-7136; 1097-0215Online Volltext: dx.doi.org/ (Open Access)
-
⁶⁸Ga]FAPI-PET/CT for radiation therapy planning in biliary tract, pancreatic ductal adeno-, and adenoidcystic carcinomasIn: Scientific Reports Jg. 12 (2022) Nr. 1,ISSN: 2045-2322Online Volltext: dx.doi.org/ (Open Access)
-
Adding cetuximab to paclitaxel and carboplatin for first-line treatment of carcinoma of unknown primary (CUP) : Results of the Phase 2 AIO trial PACET-CUPIn: British Journal of Cancer (BJC) Jg. 124 (2021) Nr. 4, S. 721 - 727ISSN: 1532-1827; 0007-0920Online Volltext: dx.doi.org/ (Open Access)
-
Antitumor immune response is associated with favorable survival in GEP-NEN G3In: Endocrine-Related Cancer Jg. 28 (2021) Nr. 10, S. 683 - 693ISSN: 1351-0088; 1479-6821Online Volltext: dx.doi.org/
-
Changes in fatigue, barriers, and predictors towards physical activity in advanced cancer patients over a period of 12 months : A comparative studyIn: Supportive Care in Cancer Jg. 29 (2021) Nr. 9, S. 5127 - 5137ISSN: 1433-7339; 0941-4355Online Volltext: dx.doi.org/ (Open Access)
-
Combined systemic inflammation score (SIS) correlates with prognosis in patients with advanced pancreatic cancer receiving palliative chemotherapyIn: Journal of Cancer Research and Clinical Oncology Jg. 147 (2021) Nr. 2, S. 579 - 591ISSN: 1432-1335; 0171-5216Online Volltext: dx.doi.org/ (Open Access)
-
Dose-escalated radiotherapy with PET/CT based treatment planning in combination with induction and concurrent chemotherapy in locally advanced (uT3/T4) squamous cell cancer of the esophagus : mature results of a phase I/II trialIn: Radiation Oncology Jg. 16 (2021) Nr. 1, S. 59ISSN: 1748-717XOnline Volltext: dx.doi.org/ (Open Access)
-
GPR15 facilitates recruitment of regulatory T cells to promote colorectal cancerIn: Cancer Research Jg. 81 (2021) Nr. 11, S. 2970 - 2982ISSN: 1538-7445; 0008-5472Online Volltext: dx.doi.org/; Online Volltext: dx.doi.org/ (Open Access)
-
Identification of a Prognostic Clinical Score for Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Treated With Systemic Therapy Including CetuximabIn: Frontiers in Oncology Jg. 11 (2021)ISSN: 2234-943XOnline Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Noninferiority of cetuximab every-2-weeks versus standard once-weekly administration schedule for the first-line treatment of RAS wild-type metastatic colorectal cancerIn: European Journal of Cancer Jg. 144 (2021) S. 291 - 301ISSN: 1879-0852; 0959-8049Online Volltext: dx.doi.org/ (Open Access)
-
A phase 1b study of the MET inhibitor capmatinib combined with cetuximab in patients with MET-positive colorectal cancer who had progressed following anti-EGFR monoclonal antibody treatmentIn: Investigational New Drugs: The Journal of New Anticancer Agents Jg. 38 (2020) S. 1774 - 1783ISSN: 1573-0646; 0167-6997Online Volltext: dx.doi.org/
-
Adjuvant MUC vaccination with tecemotide after resection of colorectal liver metastases : A randomized, double-blind, placebo-controlled, multicenter AIO phase II trial (LICC)In: OncoImmunology Jg. 9 (2020) Nr. 1,ISSN: 2162-402X; 2162-4011Online Volltext: dx.doi.org/ (Open Access)
-
Biweekly Cetuximab Plus FOLFOX6 as First-Line Therapy in Patients With RAS Wild-Type Metastatic Colorectal Cancer : The CEBIFOX TrialIn: Clinical Colorectal Cancer Jg. 19 (2020) Nr. 4, S. 236 - 247.e6ISSN: 1938-0674; 1533-0028Online Volltext: dx.doi.org/
-
Effcacy and safety of CAP7.1 as second-line treatment for advanced biliary tract cancers : Data from a randomised phase II studyIn: Cancers Jg. 12 (2020) Nr. 11, S. 1 - 16ISSN: 2072-6694Online Volltext: dx.doi.org/ (Open Access)
-
Fatigue, barriers to physical activity and predictors for motivation to exercise in advanced Cancer patientsIn: BMC Palliative Care Jg. 19 (2020) Nr. 1, S. 43ISSN: 1472-684XOnline Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Mapping Patient Data to Colorectal Cancer Clinical Algorithms for Personalized Guideline-Based TreatmentIn: Applied Clinical Informatics Jg. 11 (2020) Nr. 2, S. 200 - 209ISSN: 1869-0327Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Photochemical internalization and gemcitabine combined with first-line chemotherapy in perihilar cholangiocarcinoma: observations in three patientsIn: Endoscopy International Open Jg. 08 (2020) Nr. 12, S. E1878 - E1883ISSN: 2364-3722; 2196-9736Online Volltext: dx.doi.org/ (Open Access)
-
Stellenwert und qualitative Voraussetzungen der Magnetresonanztomografie für die Therapieplanung beim lokal fortgeschrittenen Rektumkarzinom - Interdisziplinäre EmpfehlungenIn: Zeitschrift für Gastroenterologie Jg. 58 (2020) Nr. 6, S. 577 - 582ISSN: 1439-7803; 0044-2771Online Volltext: dx.doi.org/
-
Stellenwert und qualitative Voraussetzungen der Magnetresonanztomographie für die Therapieplanung beim lokal fortgeschrittenen Rektumkarzinom – interdisziplinäre EmpfehlungenIn: Best Practice Onkologie Jg. 15 (2020) Nr. 7-8, S. 300 - 306ISSN: 1862-8559; 0946-4565Online Volltext: dx.doi.org/
-
Was erwartet der Nichtradiologe vom Radiologen?In: Der Radiologe Jg. 60 (2020) Nr. 5, S. 421 - 429ISSN: 0033-832XOnline Volltext: dx.doi.org/
-
Immunonkologie von Kopf-Hals-TumorenIn: HNO Jg. 67 (2019) Nr. 3, S. 221 - 235ISSN: 0017-6192; 1433-0458Online Volltext: dx.doi.org/
-
Impact of RAS mutation subtype on clinical outcome : a cross-entity comparison of patients with advanced non-small cell lung cancer and colorectal cancerIn: Oncogene Jg. 38 (2019) Nr. 16, S. 2953 - 2966ISSN: 0950-9232; 1476-5594Online Volltext: dx.doi.org/
-
Long-term Survival after resection for perihilar cholangiocarcinoma : Impact of UICC staging and surgical procedureIn: The Turkish Journal of Gastroenterology Jg. 30 (2019) Nr. 5, S. 454 - 460ISSN: 1300-4948Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Long-term outcome of patients with advanced pancreatic cancer treated with sequential chemotherapies before the era of modern combination therapy protocolsIn: Journal of Cancer Research and Clinical Oncology Jg. 145 (2019) Nr. 2, S. 445 - 455ISSN: 1432-1335; 0171-5216Online Volltext: dx.doi.org/
-
Natural Language Processing of German Clinical Colorectal Cancer Notes for Guideline-Based Treatment EvaluationIn: International Journal of Medical Informatics Jg. 127 (2019) S. 141 - 146ISSN: 1386-5056; 1872-8243; 1878-366XOnline Volltext: dx.doi.org/ (Open Access)
-
Nivolumab treatment beyond RECIST‐defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141 : A subgroup analysis of a randomized phase 3 clinical trialIn: Cancer Jg. 125 (2019) Nr. 18, S. 3208 - 3218ISSN: 1097-0142; 0008-543XOnline Volltext: dx.doi.org/ (Open Access)
-
Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4) : a randomised, phase 2/3 trialIn: The Lancet Jg. 393 (2019) Nr. 10184, S. 1948 - 1957ISSN: 0140-6736; 0023-7507; 1474-547XOnline Volltext: dx.doi.org/
-
Randomized phase II trial of the carboxylesterase (CES)-converted novel drug EDO-S7.1 in patients (pts) with advanced biliary tract cancers (BTC)In: Journal of Clinical Oncology Jg. 37 (2019) Nr. 4_Suppl, S. 264 - 264ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/
-
The IL-33/ST2 pathway shapes the regulatory T cell phenotype to promote intestinal cancerIn: Mucosal Immunology Jg. 12 (2019) Nr. 4, S. 990 - 1003ISSN: 1933-0219; 1935-3456Online Volltext: dx.doi.org/ (Open Access)
-
A novel biomarker combination and its association with resistance to chemotherapy combinations with bevacizumab : First results of the PERMAD trialIn: Annals of Oncology Jg. 29 (2018) Nr. Suppl. 8, S. viii159ISSN: 0923-7534; 1569-8041Online Volltext: dx.doi.org/ (Open Access)
-
CA19-9 beim intrahepatischen Cholangiokarzinom : Ein diagnostisches und prognostisches Armamentarium?In: Der Chirurg Jg. 89 (2018) Nr. 6, S. 466 - 471ISSN: 1433-0385; 0009-4722Online Volltext: dx.doi.org/
-
CheckMate 141 : 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck CancerIn: The Oncologist Jg. 23 (2018) Nr. 9, S. 1079 - 1082ISSN: 1083-7159; 2159-8401; 1549-490XOnline Volltext: dx.doi.org/ (Open Access)
-
Comparison of the sixth and the seventh editions of the UICC classification for intrahepatic cholangiocarcinomaIn: European Journal of Medical Research Jg. 23 (2018) Nr. 1, S. 29ISSN: 2047-783X; 0949-2321Online Volltext: dx.doi.org/ (Open Access)
-
Immunonkologie von Kopf-Hals-TumorenIn: Best Practice Onkologie Jg. 13 (2018) Nr. 6, S. 336 - 349ISSN: 1862-8559; 0946-4565Online Volltext: dx.doi.org/
-
MET Expression in Advanced Non–Small-Cell Lung Cancer : Effect on Clinical Outcomes of Chemotherapy, Targeted Therapy, and ImmunotherapyIn: Clinical Lung Cancer Jg. 19 (2018) Nr. 4, S. e441 - e463ISSN: 1938-0690; 1525-7304Online Volltext: dx.doi.org/
-
Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck : 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expressionIn: Oral Oncology Jg. 81 (2018) S. 45 - 51ISSN: 1879-0593; 1368-8375Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
PICCA study : panitumumab in combination with cisplatin/gemcitabine chemotherapy in KRAS wild-type patients with biliary cancer—a randomised biomarker-driven clinical phase II AIO studyIn: European Journal of Cancer Jg. 92 (2018) S. 11 - 19ISSN: 1879-2995; 0959-8049Online Volltext: dx.doi.org/
-
Phosphorylation of p70 Ribosomal Protein S6 Kinase β-1 is an Independent Prognostic Parameter in Metastatic Colorectal CancerIn: Clinical Colorectal Cancer Jg. 17 (2018) Nr. 2, S. e331 - e352ISSN: 1938-0674; 1533-0028Online Volltext: dx.doi.org/
-
PhotoChemical internalization of gemcitabine followed by gemcitabine/cisplatin in perihilar cholangiocarcinoma : Results from a phase I dose escalation trialIn: Annals of Oncology Jg. 29 (2018) Nr. Suppl. 8, S. viii259 - viii260ISSN: 0923-7534; 1569-8041Online Volltext: dx.doi.org/ (Open Access)
-
Safety profile of trifluridine/tipiracil monotherapy in clinical practice : results of the German compassionate-use program for patients with metastatic colorectal cancerIn: BMC Cancer Jg. 18 (2018) S. 1124ISSN: 1471-2407Online Volltext: dx.doi.org/ (Open Access)
-
Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1) : a randomised, double-blind, placebo-controlled phase 2 trialIn: The Lancet Oncology Jg. 18 (2017) Nr. 3, S. 323 - 335ISSN: 1470-2045Online Volltext: dx.doi.org/
-
Characterisation of Potential Predictive Biomarkers of Response to Nivolumab in Checkmate 141 in Patients With Squamous Cell Carcinoma of the Head and Neck (SCCHN)In: Asia Pac J Clin Oncol Jg. 13 4 (2017) S. 141 - 141ISSN: 1743-7555
-
Comprehensive biomarker analyses in patients with advanced or metastatic non-small cell lung cancer prospectively treated with the polo-like Kinase 1 Inhibitor BI2536In: Oncology Research and Treatment Jg. 40 (2017) Nr. 7-8, S. 435 - 439ISSN: 2296-5270; 0378-584X; 2296-5262; 1423-0240Online Volltext: dx.doi.org/
-
Docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) for resectable esophagogastric cancer : Updated results from multicenter, randomized phase 3 FLOT4-AIO trial (German Gastric Group at AIO)In: Annals of Oncology Jg. 28 5 (2017) -ISSN: 0923-7534; 1569-8041
-
High Prevalence of Concomitant Oncogene Mutations in Prospectively Identified Patients with ROS1-Positive Metastatic Lung CancerIn: Journal of Thoracic Oncology Jg. 12 (2017) Nr. 1, S. 54 - 64ISSN: 1556-1380; 1556-0864Online Volltext: dx.doi.org/ (Open Access)
-
Molecular dissection of effector mechanisms of RAS-mediated resistance to anti-EGFR antibody therapyIn: OncoTarget Jg. 8 (2017) Nr. 28, S. 45898 - 45917ISSN: 1949-2553Online Volltext: dx.doi.org/ (Open Access)
-
Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141) : health-related quality-of-life results from a randomised, phase 3 trialIn: The Lancet Oncology Jg. 18 (2017) Nr. 8, S. 1104 - 1115ISSN: 1470-2045; 1474-5488Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Perioperative chemotherapy with docetaxel, oxaliplatin and fluorouracil/leucovorin (FLOT) versus epirubicin, cisplatin and fluorouracil or capecitabine (ECF/ECX) for resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma (FLOT4-AIO) : a randoIn: Oncology Research and Treatment Jg. 40 (2017) Nr. Suppl. 3: Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, Stuttgart, 29. September-3. Oktober 2017: Abstracts, S. 200 - 201ISSN: 2296-5270; 2321-3575Online Volltext: dx.doi.org/
-
Phase I clinical study with photochemical internalisation, a novel technology for treatment of perihilar cholangiocarcinomaIn: Journal of Hepatology Jg. 66 (2017) Nr. 1, S. S452ISSN: 0168-8278; 1600-0641Online Volltext: dx.doi.org/
-
Spatiotemporally restricted arenavirus replication induces immune surveillance and type i interferon-dependent tumour regressionIn: Nature Communications Jg. 8 (2017) S. 14447ISSN: 2041-1723Online Volltext: dx.doi.org/ (Open Access)
-
Treatment beyond progression with nivolumab (nivo) in patients with recurrent or metastatic (R/M) Squamous Cell Carcinoma of the Head and Neck (SCCHN) in the phase 3 CheckMate 141 studyIn: Oncology Research and treatment Jg. 40 3 (2017) S. 250 - 251ISSN: 2296-5270; 2296-5270
-
Cholangiozelluläres Karzinom : Interventionelle und systemische TherapieoptionenIn: Der Gastroenterologe Jg. 11 (2016) Nr. 5, S. 400 - 409ISSN: 1861-9681; 1861-9681Online Volltext: dx.doi.org/
-
Circulating U2 small nuclear RNA fragments as a diagnostic and prognostic biomarker in lung cancer patientsIn: Journal of Cancer Research and Clinical Oncology Jg. 142 (2016) Nr. 4, S. 795 - 805ISSN: 0171-5216Online Volltext: dx.doi.org/
-
Differences in gene-expression in mCRC tissue samples with regard to tumor location and used chemotherapeutic substances : Data of the FIRE-1 studyIn: Journal of Clinical Oncology (JCO) Jg. 34 (2016) Nr. Suppl. 4, S. 562ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/
-
Klatskin-Tumor : Langzeitüberleben nach OperationIn: Der Chirurg Jg. 87 (2016) Nr. 6, S. 514 - 519ISSN: 0009-4722Online Volltext: dx.doi.org/
-
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and NeckIn: The New England Journal of Medicine Jg. 375 (2016) Nr. 19, S. 1856 - 1867ISSN: 1533-4406; 0028-4793Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Randomized phase II study of maintenance treatment with 5-FU/FA plus panitumumab vs 5-FU/FA alone after induction (mFOLFOX6 plus panitumumab) in patients with RAS WT metastatic colorectal cancerIn: Annals of Oncology Jg. 27 (2016) Nr. Suppl. 6, S. 605TiPISSN: 1569-8041Online Volltext: dx.doi.org/
-
Randomized, multicenter phase II trial of CAP7.1 in patients with advanced biliary tract cancers.In: Journal of Clinical Oncology (JCO) Jg. 34 (2016) Nr. Suppl. 4, S. 441 - 441ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/
-
Small cell neuroendocrine carcinoma of the right eye : A case reportIn: Oncology Research and Treatment Jg. 39 (2016) Nr. Suppl. 3, S. 189 - 189ISSN: 2296-5270
-
Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1) – a randomized, multidisciplinary, multinational phase III trialIn: Journal of Hepatology Jg. 62 (2015) Nr. Suppl. 2, S. S845ISSN: 1600-0641Online Volltext: dx.doi.org/
-
Cetuximab biweekly plus mFOLFOX6 as first-line therapy in patients (pts) with KRAS wild-type (wt) (exon 2) metastatic colorectal cancer (mCRC) : Primary endpoint and subgroup analysis of the CEBIFOX trialIn: Journal of Clinical Oncology (JCO) Jg. 33 (2015) Nr. 15 Suppl., S. 3568ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/
-
HER2 expression and markers of phosphoinositide-3-kinase pathway activation define a favorable subgroup of metastatic pulmonary adenocarcinomasIn: Lung Cancer Jg. 88 (2015) Nr. 1, S. 34 - 41ISSN: 0169-5002Online Volltext: dx.doi.org/
-
Molecular dissection of the impact of frequent genetic alterations on the response of head and neck cancers to anti-epidermal growth factor receptor-directed therapiesIn: Oral Oncology Jg. 51 (2015) Nr. 5, S. e39ISSN: 1879-0593; 1368-8375Online Volltext: dx.doi.org/
-
Development of a Highly Sensitive and Specific Method for Detection of Circulating Tumor Cells Harboring Somatic Mutations in Non-Small-Cell Lung Cancer PatientsIn: PLoS ONE Jg. 9 (2014) Nr. 1, S. e85350ISSN: 1932-6203Online Volltext: dx.doi.org/ (Open Access)
-
Formation of multiple pneumatoceles during anti-angiogenic treatment for metastatic colorectal cancerIn: Oncology Research and Treatment / Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 10.-14. Oktober 2014, Hamburg Jg. 37 (2014) Nr. Suppl. 5, S. 84 - 85ISSN: 2296-5262
-
Functional expression cloning identifies COX-2 as a suppressor of antigen-specific cancer immunityIn: Cell Death and Disease Jg. 5 (2014) Nr. 12, S. 1568ISSN: 2041-4889Online Volltext: dx.doi.org/ (Open Access)
-
Impact of human papilloma virus infection on the response of head and neck cancers to anti-epidermal growth factor receptor antibody therapyIn: Cell Death and Disease Jg. 5 (2014) Nr. 2, S. e1091ISSN: 2041-4889Online Volltext: dx.doi.org/ (Open Access)
-
Targeted therapies in gastroesophageal cancerIn: European Journal of Cancer Jg. 50 (2014) Nr. 7, S. 1247 - 1258ISSN: 1879-0852; 0959-8049Online Volltext: dx.doi.org/
-
Transient ablation of regulatory T cells improves antitumor immunity in colitis-associated colon cancerIn: Cancer Research Jg. 74 (2014) Nr. 16, S. 4258 - 4269ISSN: 1538-7445; 0008-5472Online Volltext: dx.doi.org/
-
A genome-wide RNAi screen identifies proteins modulating aberrant FLT3-ITD signalingIn: Leukemia Jg. 27 (2013) Nr. 12, S. 2301 - 2310ISSN: 1476-5551Online Volltext: dx.doi.org/
-
Cetuximab biweekly plus mFOLFOX6 as first-line therapy in patients (pts) with KRAS wild-type (wt) metastatic colorectal cancer (mCRC) : An interim analysis of the CEBIFOX trialIn: Journal of Clinical Oncology (JCO) Jg. 31 (2013) Nr. 15 Suppl., S. e14502ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/
-
Feasibility of preemptive biomarker profiling for personalised early clinical drug development at a Comprehensive Cancer CenterIn: European Journal of Cancer Jg. 49 (2013) Nr. 15, S. 3076 - 3082ISSN: 0959-8049; 1879-0852Online Volltext: dx.doi.org/
-
Oncogenic RAS simultaneously protects against anti-EGFR antibody-dependent cellular cytotoxicity and EGFR signaling blockadeIn: Oncogene Jg. 32 (2013) Nr. 23, S. 2873 - 2881ISSN: 1476-5594Online Volltext: dx.doi.org/
-
Preemptive tumor profiling for biomarker-stratified early clinical drug development in metastatic breast cancer patientsIn: Breast Cancer Research and Treatment Jg. 142 (2013) Nr. 1, S. 81 - 88ISSN: 1573-7217; 0167-6806Online Volltext: dx.doi.org/
-
Stabilization of Physical RAF/14-3-3 Interaction by Cotylenin A as Treatment Strategy for RAS Mutant CancersIn: ACS Chemical Biology Jg. 8 (2013) Nr. 9, S. 1869 - 1875ISSN: 1554-8937; 1554-8929Online Volltext: dx.doi.org/
-
Antikörper zur adoptiven Immuntherapie solider TumorenIn: Der Onkologe Jg. 18 (2012) Nr. 9, S. 757 - 769ISSN: 0947-8965; 1433-0415Online Volltext: dx.doi.org/
-
Impact of HPV status on the response of head and neck cancers to the anti-EGFR antibody cetuximabIn: Onkologie Jg. 35 (2012) Nr. Suppl. 6, S. 193 - 193ISSN: 0378-584X; 1423-0240
-
LICC: L-BLP25 in patients with colorectal carcinoma after curative resection of hepatic metastases-a randomized, placebo-controlled, multicenter, multinational, double-blinded phase II trialIn: BMC Cancer Jg. 12 (2012) S. 144ISSN: 1471-2407Online Volltext: dx.doi.org/ (Open Access)
-
Pharmacologic inhibition of mTOR antagonizes the cytotoxic activity of pemetrexed in non-small cell lung cancerIn: Journal of Cancer Research and Clinical Oncology Jg. 138 (2012) Nr. 4, S. 545 - 554ISSN: 1432-1335Online Volltext: dx.doi.org/
-
Targeting MCL-1 sensitizes FLT3-ITD-positive leukemias to cytotoxic therapiesIn: Blood Cancer Journal Jg. 2 (2012) Nr. 3, S. e60ISSN: 2044-5385Online Volltext: dx.doi.org/ (Open Access)
-
Targeting the anti-apoptotic protein BCL-XL to overcome RAS mediated resistance to anti-EGFR antibody therapy in colorectal cancerIn: Onkologie Jg. 35 (2012) Nr. Suppl. 6, S. 253ISSN: 0378-584X; 1423-0240
-
VVTZ-Tumorprofil - First results of a preemptive biomarker profiling program in relation to personalized clinical drug development at a large German Comprehensive Cancer CenterIn: Onkologie Jg. 35 (2012) Nr. Suppl. 6, S. 204 - 204ISSN: 0378-584X; 1423-0240
-
Βv-tubulin expression is associated with outcome following taxane-based chemotherapy in non-small cell lung cancerIn: British Journal of Cancer (BJC) Jg. 107 (2012) Nr. 5, S. 823 - 830ISSN: 1532-1827; 0007-0920Online Volltext: dx.doi.org/ (Open Access)
-
Comparison of PIK3CA Hot Spot Mutations in the Primary Tumor or Metastases with PIK3CA Mutations or PIK3CA Over-Expression in Circulating Tumor Cells of Metastatic Breast Cancer Patients under Sequential Palliative TherapyIn: Cancer Research Jg. 71 (2011) Nr. Suppl. 24,ISSN: 1538-7445; 0008-5472Online Volltext: dx.doi.org/
-
Evaluation of Betav-Tubulin expression as novel predictive biomarker for clinical benefit from treatment with taxanes in non-small cell lung cancerIn: Journal of Thoracic Oncology Jg. 6 (2011) Nr. Suppl. 6, S. 1078ISSN: 1556-0864; 1556-1380
-
Highly sensitive detection of somatic epidermal growth factor receptor (EGFR) gene mutations in circulating tumor cells (CTC) from patients with non-small cell lung cancer treated with cisplatin/pemetrexed or afatinibIn: Journal of Thoracic Oncology Jg. 6 (2011) Nr. Suppl. 6, S. S956 - S957ISSN: 1556-0864; 1556-1380
-
Pharmacological Inhibition of NF-k and PLK-1 to the Opening of the RAS-mediated Resistance to anti-EGFR Antibody therapies in Colorectal cancer *In: Der Internist Jg. 52 (2011) Nr. 6, S. 726 - 726ISSN: 0020-9554
-
Simultaneous protection against anti-EGFR antibody-dependent cellular cytotoxicity and EGFR-signaling blockade by oncogenic RASIn: Journal of Clinical Oncology Jg. 29 (2011) Nr. Suppl. 4, S. 440ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/
-
Tumor immunology : The new fourth pillar of tumor treatmentIn: Der Onkologe Jg. 27 (2021) Nr. 11, S. 1046 - 1048ISSN: 1433-0415; 0947-8965Online Volltext: dx.doi.org/
-
Consensus molecular subtypes (CMS) as prognostic and predictive biomarkers of panitumumab (Pmab), fluorouracil and folinic acid (FU/FA) or FU/FA maintenance therapy following Pmab-FOLFOX induction in RAS wildtype metastatic colorectal cancer (mCRC) : PANAMA trial (AIO-KRK-0212)In: Journal of Clinical Oncology (JCO) Jg. 40 (2022) Nr. 16_Suppl., S. 3537ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/
-
Negative hyperselection for mutations associated with anti-EGFR antibody resistance in RAS wildtype metastatic colorectal cancer (mCRC) : Evaluation of the PANAMA trial (AIO-KRK-0212, maintenance therapy with 5-FU, folinic acid (FU/FA) with or without panitumumab)In: Journal of Clinical Oncology (JCO) Jg. 40 (2022) Nr. 16_Suppl., S. 3536ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/
-
P-23 Phase II study (daNIS-3) of the anti–TGF-β monoclonal antibody NIS793 and other new investigational drug combinations with standard-of-care therapy vs standard-of-care alone in patients with second-line metastatic colorectal cancerIn: Annals of Oncology Jg. 33 (2022) S. 254 - S255ISSN: 1569-8041; 0923-7534Online Volltext: dx.doi.org/
-
PSMA-directed imaging and therapy of salivary gland tumors : a single-center retrospective study
EANM‘22 ; 35th Annual Congress of the European Association of Nuclear Medicine ; October 15-19, 2022, Barcelona, Spain,In: European Journal of Nuclear Medicine and Molecular Imaging Jg. 49 (2022) Nr. Supplement 1, S. S229ISSN: 1619-7089; 1619-7070; 0340-6997; 1432-105XOnline Volltext: dx.doi.org/ (Open Access) -
Predictive and prognostic value of carcinoembryonic antigen (CEA) on maintenance therapy with 5-fluoruracil/leucovorin plus panitumumab or 5-fluoruracil/leucovorin alone in RAS wildtype metastatic colorectal cancer : Evaluation of the phase II PanaMa trial (AIO KRK 0212)In: Journal of Clinical Oncology (JCO) Jg. 40 (2022) Nr. 16_Suppl., S. 3587ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/
-
Randomized study to investigate a switch maintenance concept with 5-FU plus bevacizumab after FOLFIRI plus cetuximab induction treatment versus continued treatment with FOLFIRI plus cetuximab : Report of a secondary endpoint of the phase-III FIRE-4 study (AIO KRK-0114)In: Journal of Clinical Oncology (JCO) Jg. 40 (2022) Nr. 16_Suppl., S. 3519ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/
-
SO-16 FIRE-4 (AIO-KRK-0114) : Randomized study for a switch maintenance concept with 5-FU plus bevacizumab after induction treatment with FOLFIRI plus cetuximab versus continued treatment with FOLFIRI plus cetuximab – secondary endpointIn: Annals of Oncology Jg. 33 (2022) Nr. Suppl. 4, S. 363 - S364ISSN: 1569-8041; 0923-7534Online Volltext: dx.doi.org/
-
Superiority of [68Ga]Ga-FAPI-46 over [18F]F-FDG PET/CT for cholangiocarcinoma imaging
EANM‘22 ; 35th Annual Congress of the European Association of Nuclear Medicine ; October 15-19, 2022 Barcelona, Spain,In: European Journal of Nuclear Medicine and Molecular Imaging Jg. 49 (2022) Nr. Supplement 1, S. S192 - S193ISSN: 1619-7089; 1619-7070; 0340-6997; 1432-105XOnline Volltext: dx.doi.org/ (Open Access) -
Target Expression and FAP-Directed Tumour Imaging in a Large, Single-Centre PET Database of 324 Patients and 21 Tumour Entities
EANM‘22 ; 35th Annual Congress of the European Association of Nuclear Medicine ; October 15-19, 2022, Barcelona, Spain,In: European Journal of Nuclear Medicine and Molecular Imaging Jg. 49 (2022) Nr. Supplement 1, S. S119 - S120ISSN: 1619-7089; 1619-7070; 0340-6997; 1432-105XOnline Volltext: dx.doi.org/ (Open Access) -
ELDORANDO : Pembrolizumab compared with methotrexate in elderly, frail or cisplatin-ineligible patients with relapsed or metastatic squamous cell carcinoma of the head and neck (RM-SCCHN) (ELDORANDO-AIO-KHT-0115)
Gemeinsame Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie ; 01.-04. Oktober 2021, Hybrid-Kongress,In: Oncology Research and Treatment Jg. 44 (2021) Nr. Supplement 2, S. 56 - 57ISSN: 2296-5262; 2296-5270; 1423-0240; 0378-584XOnline Volltext: dx.doi.org/ (Open Access) -
Efficacy of immunotherapy (IO) and subsequent systemic treatment after failure of IO in patients with recurrent or metastatic head and neck cancer in a real-world settingIn: Annals of Oncology Jg. 32 (2021) Nr. Suppl. 5, S. 812ISSN: 1569-8041; 0923-7534Online Volltext: dx.doi.org/ (Open Access)
-
Maintenance therapy with 5-fluoruracil/leucovorin (5FU/LV) plus panitumumab (pmab) or 5FU/LV alone in RAS wildtype (WT) metastatic colorectal cancer (mCRC) - the PANAMA trial (AIO KRK 0212)In: Journal of Clinical Oncology Jg. 39 (2021) Nr. 15_Suppl, S. 3503 - 3503ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/
-
Phase (Ph) II study of taminadenant (NIR178) + spartalizumab (PDR001) in patients (pts) with microsatellite stable (MSS) colorectal cancer (CRC)In: Annals of Oncology Jg. 32 (2021) Nr. Suppl. 5, S. 552 - S553ISSN: 1569-8041; 0923-7534Online Volltext: dx.doi.org/ (Open Access)
-
Predicting resistance to first-line FOLFOX plus bevacizumab in metastatic colorectal cancer : Final results of the multicenter, international PERMAD trial
2021 Gastrointestinal Cancers Symposium ; January 15-17, 2021, Virtuell,In: Journal of Clinical Oncology (JCO) Jg. 39 (2021) Nr. 3, Supplement, S. 115 - 115ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/ -
Prognostic Significance of the metabolic Response during Induction Chemotherapy for the definitive Chemoradiotherapy of locally advanced Squamous Cell Carcinoma of the EsophagusIn: Strahlentherapie und Onkologie: Journal of Radiation Oncology, Biology, Physics Jg. 197 (2021) Nr. Suppl. 1, S. 154 - S155ISSN: 1439-099X; 0179-7158
-
RAMucirumab in combination with TAS102 versus TAS102 monotherapy in metastatic colorectal cancer : Safety results from the phase IIb part of the RAMTAS phase II/III trial of the German AIO (AIO-KRK-0316)In: Journal of Clinical Oncology Jg. 39 (2021) Nr. 15_Suppl, S. 3566 - 3566ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/
-
Randomized study to investigate FOLFOXIRI plus either bevacizumab or cetuximab as first-line treatment of BRAF V600E-mutant mCRC : The phase-II FIRE-4.5 study (AIO KRK-0116)In: Journal of Clinical Oncology Jg. 39 (2021) Nr. 15_Suppl, S. 3502 - 3502ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/
-
Results of a randomized phase II study comparing pembrolizumab with methotrexate in elderly, frail or cisplatin-ineligible patients with relapsed or metastatic squamous cell carcinoma of the head and neck (RM-SCCHN) (ELDORANDO-AIO-KHT-0115)In: Annals of Oncology Jg. 32 (2021) Nr. Suppl. 5, S. 807 - S808ISSN: 1569-8041; 0923-7534Online Volltext: dx.doi.org/ (Open Access)
-
Interim safety analysis of the phase IIb study of ramucirumab in combination with TAS102 vs. TAS102 monotherapy in metastatic colorectal cancer : The RAMTAS trial of the German AIOIn: Annals of Oncology Jg. 31 (2020) Nr. Suppl. 4, S. S427 - S428ISSN: 0923-7534Online Volltext: dx.doi.org/ (Open Access)
-
Patients with metastatic EGFR-mutated non-small cell lung cancer (NSCLC) show highly favorable outcomes with treatment sequences provided at a comprehensive cancer center
Virtuelle Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 09.–11. Oktober 2020,In: Oncology Research and Treatment Jg. 43 (2020) Nr. Suppl. 4, S. 137ISSN: 2296-5270; 2296-5262; 1423-0240; 0378-584XOnline Volltext: dx.doi.org/ (Open Access) -
A phase IIb study of ramucirumab in combination with TAS102 versus TAS102 monotherapy in metastatic, chemotherapy refractory colorectal cancer patients : The RAMTAS trial of the German AIO (KRK-0316)In: Journal of Clinical Oncology Jg. 37 (2019) Nr. 15, S. TPS3617 - TPS3617ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/
-
PET-directed combined modality therapy for gastroesophageal junction cancer : First results of the prospective MEMORI trialIn: Journal of Clinical Oncology Jg. 37 (2019) Nr. 15, S. 4018 - 4018ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/
-
Paclitaxel/carboplatin with or without cetuximab for treatment of carcinoma with unknown primary (PACET-CUP) : Results of a multi-center randomized phase II AIO trialIn: Journal of Clinical Oncology (JCO) Jg. 37 (2019) Nr. 15, S. 4120ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/
-
Phase Ib study of MIW815 (ADU-S100) in combination with spartalizumab (PDR001) in patients (pts) with advanced/metastatic solid tumors or lymphomasIn: Journal of Clinical Oncology (JCO) Jg. 37 (2019) Nr. 15, S. 2507 - 2507ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/
-
A novel biomarker combination and its association with resistance to chemotherapy combinations with bevacizumab : First results of the PERMAD trialIn: Journal of Clinical Oncology (JCO) Jg. 36 (2018) Nr. Suppl. 15, S. e15545 - e15545ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/
-
Efficacy and safety of Trifluridin/Tipiracil (FTD/TPI) (Lonsurf (R)) in patients with metastatic colorectal cancer (CRC) in clinical-routine use
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie ; 28. September - 2. Oktober 2018, Wien,In: Oncology Research and Treatment Jg. 41 (2018) Nr. Suppl. 4, S. 289ISSN: 2296-5262; 2296-5270Online Volltext: dx.doi.org/ (Open Access) -
Evaluation of prognostic markers in patients (pts) with advanced gastric cancer (GC) and adenocarcinoma of the gastroesophageal junction (AEG) treated with systemic chemothearpy (ctx) at the West German Cancer Center
33. Deutscher Krebskongress - Perspektiven verändern Krebs - Krebs verändert Perspektiven. Diagnose - Therapie - (Über-)Leben ; 21.-24. Februar 2018, Berlin,In: Oncology Research and Treatment Jg. 41 (2018) Nr. Suppl. 1, S. 67ISSN: 2296-5270; 2296-5262Online Volltext: dx.doi.org/ (Open Access) -
Nivolumab (Nivo) vs Investigator‘s Choice (IC) for Platinum-Refractory (PR) Recrrent or Metastatic (R/M) Squamous Cell Carcinoma of the Head and Neck (SCCHN; CheckMate 141) : Outcomes in First-line (1L) R/M Patients (Pts) and Updated Safety and Efficacy
33. Deutscher Krebskongress - Perspektiven verändern Krebs - Krebs verändert Perspektiven. Diagnose - Therapie - (Über-)Leben ; 21.-24. Februar 2018, Berlin,In: Oncology Research and Treatment Jg. 41 (2018) Nr. Suppl. 1, S. 96ISSN: 2296-5262; 2296-5270Online Volltext: dx.doi.org/ (Open Access) -
Nivolumab (Nivo) vs investigator's choice (IC) in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) : 2-yr outcomes in the overall population and PD-L1 subgroups of CheckMate 141In: Cancer Research Jg. 78 (2018) Nr. Suppl. 13,ISSN: 1538-7445; 0008-5472Online Volltext: dx.doi.org/
-
PD-L1 mRNA expression in patients with resectable gastric cancer and adenocarcinoma of the oesophago-gastric junction undergoing perioperative chemotherapy : Results from the FLOT4 phase III trial of the AIOIn: Journal of Clinical Oncology (JCO) Jg. 36 (2018) Nr. Suppl. 15, S. e24277 - e24277ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/ (Open Access)
-
Signaling network activation in colorectal cancer : p70S6K phosphorylation as a prognostic marker
33. Deutscher Krebskongress - Perspektiven verändern Krebs - Krebs verändert Perspektiven. Diagnose - Therapie - (Über-)Leben ; 21.-24. Februar 2018, Berlin,In: Oncology Research and Treatment Jg. 41 (2018) Nr. Suppl. 1, S. 55ISSN: 2296-5270; 2296-5262Online Volltext: dx.doi.org/ (Open Access) -
The prognostic impact of UDP-glucuronyltransferase 1A1*1 (UGT1A1*1) polymorphism in patients with advanced colorectal and non-colorectal cancer treated with irinotecan-based systemic chemotherapies
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie ; 28. September - 2. Oktober 2018, Wien,In: Oncology Research and Treatment Jg. 41 (2018) Nr. Suppl. 4, S. 122 - 123ISSN: 2296-5262; 2296-5270Online Volltext: dx.doi.org/ (Open Access) -
Two-year Update From CheckMate 141 : Outcomes With Nivolumab (Nivo) vs Investigator's Choice (IC) in Recurrent or Metastatic (R/M) Squamous Cell Carcinoma of the Head and Neck (SCCHN) in the Overall Population and PD-L1 SubgroupsIn: International Journal of Radiation Oncology Biology Physics Jg. 100 (2018) Nr. 5, S. 1317 - 1317ISSN: 0360-3016
-
Nivolumab vs investigator's choice (IC) in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) : treatment effect on clinical outcomes by best overall response in checkmate 141
42nd ESMO Congress (ESMO 2017) ; 8-12 September 2017, Madrid, Spain,In: Annals of Oncology Jg. 28 (2017) Nr. Suppl. 5, S. v377 - v378ISSN: 0923-7534; 1569-8041Online Volltext: dx.doi.org/ -
Treatment beyond progression with nivolumab in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) in the phase 3 checkmate 141 study : A biomarker analysis and updated clinical outcomes
42nd ESMO Congress (ESMO 2017) ; 8-12 September 2017, Madrid, Spain,In: Annals of Oncology Jg. 28 (2017) Nr. Suppl. 5, S. v372 - v373ISSN: 0923-7534; 1569-8041Online Volltext: dx.doi.org/ -
Evaluation of prognostic markers in patients (pts) with metastatic colorectal cancer (mCRC) treated with a bevacizumab (bev) based chemotherapy (ctx) at the West German Cancer Center
Krebsmedizin heute: präventiv, personalisiert, präzise und partizipativ ; 32. Deutscher Krebskongress ; 24.-27. Februar 2016, Berlin,In: Oncology Research and Treatment Jg. 39 (2016) Nr. Suppl. 1, S. 77ISSN: 2296-5270; 2296-5262; 1423-0240; 0378-584XOnline Volltext: dx.doi.org/ -
Evaluation of systemic inflammatory response (SIR) markers in recurrent or metastatic head and neck squamous cell carcinoma (r/m HNSCC)In: Oncology Research and Treatment Jg. 39 (2016) Nr. Suppl. 3, S. 307 - 308ISSN: 2296-5270Online Volltext: dx.doi.org/
-
Evaluation of systemic inflammatory response (SIR) markers in advanced biliary tract cancer (ABTC)
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 9.-13. Oktober 2015, Basel, Schweiz,In: Oncology Research and Treatment Jg. 38 (2015) Nr. Suppl. 5, S. 5 - 6ISSN: 2296-5270; 0378-584X; 2296-5262; 1423-0240Online Volltext: dx.doi.org/ -
Evaluation of systemic inflammatory response (SIR) markers in pancreatic ductal adenocarcinoma (PDAC)In: Oncology Research and Treatment Jg. 38 (2015) Nr. S 5, Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 9.-13. Oktober 2015, Basel, Schweiz, S. 4 - 5ISSN: 2296-5270; 0378-584X; 1423-0240; 2296-5262Online Volltext: dx.doi.org/
-
Prognostische Faktoren bei Patienten mit fortgeschrittenen Pankreaskarzinomen, die am Westdeutschen Tumorzentrum (WTZ) sequentielle Chemotherapien erhalten haben.
121. Kongress der Deutschen Gesellschaft für Innere Medizin e.V. 18. - 21. April 2015, Mannheim,In: Der Internist Jg. 56 (2015) Nr. S1, S. 38 - 39ISSN: 0020-9554; 1432-1289Online Volltext: dx.doi.org/ -
Prognostische Faktoren bei Patienten mit fortgeschrittenen cholangiozellulären Karzinomen, die am Westdeutschen Tumorzentrum (WTZ) sequentielle Chemotherapien erhalten haben
121. Kongress der Deutschen Gesellschaft für Innere Medizin e.V., 18. - 21. April 2015, Mannheim,In: Der Internist Jg. 56 (2015) Nr. S 1, S. 37ISSN: 1432-1289Online Volltext: dx.doi.org/ -
A randomized, double-blind, placebo-controlled, multicenter, binational, phase II trial of immunotherapy with L-BLP25 (tecemotide) in patients with colorectal carcinoma following R0/R1 hepatic metastasectomyIn: Journal of Clinical Oncology (JCO) Jg. 32 (2014) Nr. 15, suppl., S. TPS3658ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/
-
Cetuximab biweekly plus mFOLFOX6 as first-line therapy in patients (pts) with KRAS wild-type (wt) metastatic colorectal cancer (mCRC) - Primary endpoint analysis of the CEBIFOX trial
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 10.-14. Oktober 2014, Hamburg,In: Oncology Research and Treatment Jg. 37 (2014) Nr. Suppl. 5, S. 99 - 100ISSN: 2296-5262Online Volltext: dx.doi.org/ -
Circulating U2 small nuclear RNA fragments as a diagnostic and prognostic biomarker in lung cancer patients
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 10.-14. Oktober 2014, Hamburg,In: Oncology Research and Treatment Jg. 37 (2014) Nr. Suppl. 5, S. 226 - 227ISSN: 2296-5262Online Volltext: dx.doi.org/ -
Impact of human papilloma virus infection on the response of head and neck cancers (HNSCC) to anti-epidermal growth factor receptor (EGFR) antibody therapy
31. Deutscher Krebskongress iKON - intelligente Konzepte in der Onkologie, 19.-22. Februar 2014, Berlin,In: Oncology Research and Treatment Jg. 37 (2014) Nr. Suppl. 1, S. 76ISSN: 2296-5262Online Volltext: dx.doi.org/ -
Molecular and clinical predictors of the efficacy of cetuximab in combination with mFOLFOX6 in 1st line treatment of patients (pts) with metastatic colorectal cancer (mCRC) – subgroup analyses of the CEBIFOX trial
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 10.-14. Oktober 2014, Hamburg,In: Oncology Research and Treatment Jg. 37 (2014) Nr. Suppl. 5, S. 100 - 101ISSN: 2296-5262Online Volltext: dx.doi.org/ -
Outcome of patients (pts) with advanced pancreaticobiliary cancers treated with sequential chemotherapies at the West German Cancer Center (WTZ)
Deutscher Krebskongress iKON - intelligente Konzepte in der Onkologie, 19.-22. Februar 2014, Berlin,In: Oncology Research and Treatment Jg. 37 (2014) Nr. Suppl. 1, S. 51ISSN: 2296-5262Online Volltext: dx.doi.org/ -
Preemptive tumor profiling for biomarker-stratified early clinical drug development in metastatic breast cancer patientsIn: Oncology Research and Treatment Jg. 37 (2014) Nr. Suppl. 1: 31. Deutscher Krebskongress iKON - intelligente Konzepte in der Onkologie Berlin, 19.-22. Februar 2014: Abstracts, S. 19ISSN: 2296-5262Online Volltext: dx.doi.org/ (Open Access)
-
Prognostic factors in patients (pts) with advanced cholangiocellular carcinoma (CCC) receiving sequential chemotherapies (CTX) at the West German Cancer Center (WTZ)
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 10.-14. Oktober 2014, Hamburg,In: Oncology Research and Treatment Jg. 37 (2014) Nr. Suppl. 5, S. 122 - 123ISSN: 2296-5262Online Volltext: dx.doi.org/ -
Prognostic factors in patients with pancreatic cancer receiving sequential chemotherapies (CTX) at the West German Cancer Center (WTZ), one of the 12 Oncology Centers of Excellence in Germany
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 10.-14. Oktober 2014, Hamburg,In: Oncology Research and Treatment Jg. 37 (2014) Nr. Suppl. 5, S. 123 - 124ISSN: 2296-5262Online Volltext: dx.doi.org/ -
WTZ-Tumorprofil-A preemptive biomarker profiling program in relation to personalized clinical drug development at a large German Comprehensive Cancer Center : Two years experience
31. Deutscher Krebskongress iKON - intelligente Konzepte in der Onkologie, 19.-22. Februar 2014, Berlin,In: Oncology Research and Treatment Jg. 37 (2014) Nr. Suppl. 1, S. 2 - 3ISSN: 2296-5262Online Volltext: dx.doi.org/ -
Molecular dissection of effector mechanisms of RAS-induced resistance to monoclonal anti-EGFR antibodies
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Onkologie, 18.-22. Oktober 2013, Wien, Österreich,In: Onkologie Jg. 36 (2013) Nr. Suppl. 7, S. 116 - 117ISSN: 0378-584X; 1423-0240Online Volltext: dx.doi.org/ -
Outcome of patients (pts) with advanced pancreaticobiliary cancers treated with sequential chemotherapies at the West German Cancer Center (WTZ), one of the 11 Oncology Centers of Excellence in Germany
17 Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Onkologie, 18.-22. Oktober 2013, Wien, Österreich,In: Onkologie Jg. 36 (2013) Nr. Suppl. 7, S. 263ISSN: 0378-584X; 1423-0240Online Volltext: dx.doi.org/ -
Preemptive tumor profiling for biomarker-stratified early clinical drug development in metastastic breast cancer patients
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Onkologie, 18.-22. Oktober 2013, Wien, Österreich,In: Oncology Research and Treatment Jg. 36 (2013) Nr. Suppl. 7, S. 157ISSN: 0378-584X; 1423-0240Online Volltext: dx.doi.org/ -
Targeting NF-kappa B and PLK-1 to overcome RAS-mediated resistance to anti-EGFR antibody therapy in colorectal cancer
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Onkologie. Berlin, 1.–5. Oktober 2010,In: Onkologie Jg. 33 (2010) Nr. Suppl. 6, S. 33ISSN: 0378-584X; 1423-0240; 2296-5270; 2296-5262Online Volltext: dx.doi.org/ -
Therapeutische Modulation onkogener Signaltransduktion bei malignen Erkrankungen und Mechanismen der ResistenzentwicklungDuisburg, Essen (2014) 1 CD-ROM